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ABSTRACT 
Background: Rheumatoid arthritis (RA) is an incurable autoimmune disease that can 
cause permanent joint damage and loss of function. Anti-tumor necrosis factor (anti-
TNF) agents inhibit the function of tumor necrosis factor (TNF), which leads to a 
reduction in the progression of joint damage due to inflammation. However, an 
increased risk of serious infections in RA patients using anti-TNF agents has been 
observed in previous studies. This increased risk may be due to the immunologic 
disturbance of the RA disease process itself, the immunosuppressive properties of 
anti-rheumatic drug therapies, or co-existing risk factors for infection present in RA 
patients. Herein, our aim is to assess potential predictors of hospitalized infection in 
RA patients using anti-TNF agents. 
Objective: Our objective is to determine if patients with RA who are prescribed the 
anti-TNF agents; adalimumab, etanercept, or infliximab, are at an increased risk of 
having a serious infection. In addition, we sought to identify potential predictors of an 
increased risk of infection in RA patients using anti-TNF agents.  
Methods: A nested case-control study was conducted using de-identified data from 
the ClinformaticsTM DataMart (OptumInsight, Eden Prairie, MN), an administrative 
health claims database from a large national private insurer. An initial cohort of 
78,657 patients with ≥1 RA diagnosis was identified. Patients were included from this 
initial cohort based on age, enrollment eligibility, number of RA diagnoses, exposure 
to an anti-TNF agent, and excluded based on certain comorbidities. A final RA cohort 
sample of 15,181 patients was formed. A follow-up period of 1 year was selected to 
analyze serious infections requiring hospitalization; these events were identified with a 
  
comprehensive set of ICD-9 codes for serious infections requiring inpatient admission. 
Patients were classified as cases if they experienced a serious infection during the 1-
year follow up. The final selected cases and controls were matched on a 1:1 ratio 
based on gender, region, and RA cohort entry date (quarter, year). A total of 155 cases 
and 155 controls were identified. Both univariable and multivariable conditional 
logistic regression models were built to produce a final multivariable predictive 
model. 
Results: Among, RA patients using anti-TNF agents, those with recent prednisone use 
were 1.873 times more likely to have a hospitalized infection (95% confidence interval 
[CI] 1.015-3.458). Patients with comorbid diabetes were 2.963 times more likely to 
experience a hospitalized infection (95% CI 1.445-6.078) and patients with comorbid 
chronic obstructive pulmonary disease (COPD) were 9.233 times more likely to 
experience a hospitalized infection (95% CI 2.755-30.947). Lastly, patients with a 
previous history of infection were 8.984 times more likely to have a hospitalized 
infection (95% CI 1.895-42.595). No associations between anti-TNF agent 
(adalimumab, infliximab, or etanercept) or incident/prevalent anti-TNF use and 
hospitalized infection were observed. 
Conclusion: The use of specific anti-TNF agents was not independently associated 
with an increased risk of hospitalized infection in RA patients. Predictors associated 
with hospitalized infection in RA patients using anti-TNF agents included recent 
prednisone use, comorbid diabetes, comorbid COPD, and previous history of 
infection. 
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CHAPTER 1 
 
INTRODUCTION 
 
Rheumatoid arthritis (RA) is an autoimmune disease characterized by the chronic 
inflammation of synovial joints causing persistent pain and stiffness that can 
eventually result in joint deformities and loss of function.1 Given the debilitating 
nature of RA, the disease poses a significant negative impact on health-related quality 
of life.2,3 In 2005, an estimated 1.3 million (0.6%) adults had RA in the United States 
(US).4 There is no cure available for RA, but the condition can be managed to slow 
down the progression of disease and improve a patient’s quality of life. Current 
treatment options for RA include non-steroidal anti-inflammatory drugs (NSAIDs), 
traditional disease-modifying anti-rheumatic drugs (DMARDs), and biologic 
DMARDs. The type of treatment used depends on a patient’s disease activity, signs 
and symptoms, and prognosis. The current treatment model for RA focuses on an 
early, aggressive combination therapy approach by prescribing a combination of 
multiple drugs early on in order to achieve adequate disease control as quickly as 
possible.5 
Biologic DMARDs, particularly anti-tumor necrosis factor (anti-TNF) drugs have 
emerged as important agents in the treatment of RA, especially in patients who have 
failed to respond to traditional DMARDs alone. Anti-TNF medications approved by 
the US Food and Drug Administration (FDA) for a number of conditions including 
rheumatoid arthritis, juvenile idiopathic arthritis, Crohn’s disease, ulcerative colitis, 
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psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis.6 The introduction of 
anti-TNF drugs beginning in the late 1990s revolutionized the treatment of rheumatoid 
arthritis (RA) as they have been shown to be very effective at reducing inflammation 
in RA patients.7-9 
Tumor necrosis factor (TNF) plays an important role in host cell defense as a pro-
inflammatory cytokine involved in systemic inflammation.10 This inflammatory 
response against harmful bacteria and viruses is controlled and regulated by the body 
under normal conditions. In patients with RA, macrophages overproduce TNF leading 
to inflammation of the joints. Anti-TNF agents inhibit the function of TNF by 
preventing TNF from binding to its receptor, which reduces the progression of joint 
damage due to inflammation.10,11  
An uncommon, yet significant side effect associated with anti-TNF drug use is 
the increased risk of serious infections.12,14-16 The prescribing information for the anti-
TNF agents; adalimumab, etanercept, and infliximab contains black box warnings 
ordered by the FDA indicating the increased risk of serious infection leading to 
hospitalization or death and recommending discontinued use if a patient develops a 
serious infection.17-19 This increased risk of infection may be due to the immunologic 
disturbance of the RA disease process, the immunosuppressive properties of anti-
rheumatic drug therapies, or co-existing risk factors for infection present in RA 
patients. Most likely, this increased risk of infection is due to a combination of these 
different factors.12-15 
A retrospective longitudinal cohort study published by Doran et al20 in 2002 
compared infection rates in a group of patients with RA with those in a group of 
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individuals without RA. The study reported results from a cohort of Rochester, 
Minnesota residents who were first diagnosed as having RA between 1955 and 1994. 
Study subjects were followed until death, migration from the area, or study end 
(January 1, 2000), whichever came first. Among 609 patients with incident RA in 
1955-1994, 290 (47.6%) experienced ≥1 serious infection. Infections requiring 
hospitalization were significantly more frequent in RA patients (9.57/100 person-
years) than in non-RA study subjects (5.09/100 person-years) with a rate ratio of 1.88 
(95% confidence interval [CI] 1.71-2.07). In other words, the researchers found that 
the risk of developing a serious infection requiring hospitalization in patients with RA 
was estimated to be nearly two-fold in comparison with non-RA patients. As this 
study occurred before anti-TNF agents were widely available for the treatment of RA, 
the increased risk of infection in RA patients was well established before the 
introduction of anti-TNF agents to the RA drug market. 
Research to better understand the risk factors associated with the increased rate of 
hospitalized infection in RA patients using anti-TNF agents remains limited, 
particularly among patient populations within the US. The lack of studies focusing on 
risk factors establishes a need for further research to identify potential predictors of 
hospitalized infection in this patient population using medications which can increase 
their risk of infection.  
Therefore, the objective of this study was to determine whether specific anti-TNF 
agents, adalimumab, etanercept, or infliximab, increased the risk of hospitalized 
infection. A secondary objective was to identify potential predictors for hospitalized 
infection in RA patients using anti-TNF agents. These findings will help inform 
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clinicians and patients about factors that may affect the development of serious 
infections. 
The hypothesis for this study is that the odds of hospitalized infection among RA 
patients using anti-TNF agents will be greater in patients with older ages, 
corticosteroid use, disease modifying anti-rheumatic drug (DMARD) use, and 
comorbidities such as diabetes mellitus, chronic kidney disease, and chronic 
obstructive pulmonary disorder. 
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CHAPTER 2 
 
REVIEW OF LITERATURE 
 
Although numerous studies have explored the association between anti-TNF use 
and an increased risk of infection, fewer studies in comparison have focused on 
identifying additional potential predictors of hospitalized infection in RA patients 
treated with these medications. 
Studies were eligible for inclusion into the literature review based on several 
broad criteria. We searched for studies using PubMed, the Cochrane databases, and 
Google Scholar and identified studies published from 2007 to 2013. First, the 
reviewed studies had to have a study cohort comprised of only RA patients defined as 
having ≥1 RA diagnosis. Second, exposures of interest had to include the anti-TNF 
agents, adalimumab, etanercept, and infliximab. Studies that evaluated newer anti-
TNF agents such as golimumab and certolizumab pegol were not included into our 
literature review.  And lastly, the outcome of interest had to include, but was not 
limited to serious infection requiring hospitalization. Appendix 1 lists the selected 
studies with further details on study design, patient population, inclusion and 
exclusion criteria, exposure and outcome, and significant predictors. 
A retrospective cohort study by Curtis et al12 published in 2007 used data from 
the medical and pharmacy administrative claims of a large US health care 
organization. The objective of this study was to evaluate the risk of serious bacterial 
infections in RA patients using anti-TNF agents and traditional DMARDs alone. 
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Researchers found that the adjusted hazard ratio (HR) of hospitalized bacterial 
infection among patients who received anti-TNF drugs was 1.9 (95% confidence 
interval [CI] 1.3–2.8) compared with patients who received methotrexate only. In 
other words, the risk of hospitalized bacterial infection was approximately 2-fold 
higher among patients receiving anti-TNF agents versus patients receiving 
methotrexate alone. Significant predictors of infection included anti-TNF use, older 
age, number of physician visits, prior infection, concomitant prednisone use, and 
presence of comorbidities, including chronic obstructive pulmonary disease/asthma, 
diabetes mellitus, and kidney disease. 
A retrospective cohort study by Favalli et al21 published in 2009 used data from 
the regional population-based Lombardy Rheumatology Network (LORHEN) registry 
consisting of RA patients using anti-TNF agents from four major Rheumatology Units 
in Lombardy, Italy. The objective of the study was to estimate the incidence of serious 
infections in the patients treated with anti-TNF agents and identify significant 
predictors of infection. The researchers found that 6.9% of patients in the eligible 
cohort experienced a serious infection requiring hospitalization and/or intravenous 
antibiotic therapy with an overall incidence rate of 3.59/100 patient-years (95% CI 
2.77–4.41). Significant predictors of infection included age (per 1 year), concomitant 
prednisone use, and erythrocyte sedimentation rate (ESR). 
A retrospective cohort study by Atzeni et al22 published in 2012 used data from 
the nationwide Gruppo Italiano Studio Early Arthritis (GISEA) registry, which 
registers and monitors rheumatic patients treated with biological drugs at hospital and 
community-based rheumatology units throughout Italy. The objective of the study was 
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to assess the risk of serious infections in RA patients using anti-TNF therapy and 
identify potential risk factors. The researchers found that 6.36% of patients over a 
follow-up time of 9 years in the eligible cohort experienced a serious infection 
requiring hospitalization or intravenous antibiotic therapy with an overall incidence 
rate of 3.18/100 patient-years (95% CI 2.52–3.83). Significant predictors of infection 
included corticosteroid therapy, concomitant DMARD therapy, and age at the start of 
anti-TNF treatment. 
A nested case-control study by Widdifield et al23 published in 2013 used data 
from the Ontario Health Insurance Plan (OHIP) Database, an administrative claims 
database comprised of patients in Ontario, Canada. The objective of the study was to 
identify the risk of infection in a cohort of seniors with RA using anti-TNF agents in 
the OHIP database and identify potential risk factors for infection. The researchers 
found that 23.91% of patients over a follow-up time of 12 years in the eligible cohort 
experienced a serious infection requiring hospitalization or an ER visit for an 
incidence rate of 4.64 events/100 patient years (95% CI not reported). Significant 
predictors of infection included rural residence, diabetes mellitus, chronic lung 
disease, renal disease, glucocorticoid use ≤5 mg/day, glucocorticoid use ≥20 mg/day, 
methotrexate use ≤10 mg/day, methotrexate use >10 mg/day, anti-TNF use, extra 
articular features of RA, joint replacements, and history of previous infection. 
A retrospective cohort study by van Dartel24 et al published in 2013 used data 
from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. The objective of 
the study was to identify predictors of the increased risk of serious infections in RA 
patients treated with anti-TNF agents. Researchers found that 6.3% of patients over a 
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follow-up time of 5 years in the eligible cohort developed a serious infection requiring 
hospitalization and/or intravenous antibiotic therapy. The incidence rate in the first 
year after the initiation of anti-TNF therapy was 4.57/100 patient-years and 2.91/100 
patient-years over 5 years (95% CI not reported). Significant predictors of infection 
included older age, corticosteroid use, visual analogue scale (VAS) pain, Health 
Assessment Questionnaire (HAQ), tender joint count 28 joints (TJC28), and presence 
of comorbidities. 
From a review of the literature, the majority of studies that investigate possible 
risk factors for infection in RA patients using anti-TNF agents have been performed 
using data from rheumatic disease registries and healthcare databases from outside of 
the United States. The one US study by Curtis et al12, included patients with and 
without anti-TNF use. Significant predictors of infection that were common across the 
studies reviewed included increased age, corticosteroid use, DMARD use, and 
presence of comorbidities such as diabetes, chronic kidney disease, and chronic 
obstructive pulmonary disorder (COPD).  
The objective of this study was to assess risk factors for serious infections 
requiring hospitalization in RA patients using anti-TNF agents. This study will 
provide clinicians and RA patients with more knowledge on which factors are 
predictive of an increased risk of infection which may help reduce and prevent such 
infections. Furthermore, the use of a large, national administrative claims database 
representative of the privately insured population in the United States will produce 
more generalizable results on potential risk factors for infection among patients with 
RA in the United States. 
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CHAPTER 3 
 
METHODOLOGY 
 
Study Design and RA Cohort Definition 
A nested case-control study was conducted using data from the ClinformaticsTM 
DataMart (OptumInsight, Eden Prairie, MN), an administrative health claims database 
from a large national private insurer. The database contains de-identified patient level 
data across multiple categories including medical claims, pharmacy claims, and 
administrative data. We selected a nested case-control design because it is efficient for 
the study of rare outcomes and good for assessing multiple exposures. The outcome of 
interest in this study, hospitalized infection, is relatively rare with rates of infection 
ranging from 6-7% during extended follow-up time periods.22,24 Data from the study 
time period of January 1, 2010 to December 31, 2013 was used in the analyses. 
For inclusion into the RA cohort, both cases and controls had to be 18 to 63 years 
old at the time of their entry into the RA cohort (for a timeline of the RA cohort, 
please see Figure 1). Both cases and controls had to have ≥2 RA diagnoses 
(International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-
9-CM] code for RA of 714.x) separated by >7 days and occurring within 1 year of 
each other. Patients also had to have continuous enrollment for ≥2 years. More 
specifically, patients had to be continuously enrolled for the 12-months before the first 
RA diagnosis and the 12-months after the first RA diagnosis. The RA cohort entry 
date is defined as the date of the first RA diagnosis in which all the predefined RA 
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cohort criteria were met. The reasoning for requiring continuous enrollment in the 12-
months prior to the first RA diagnosis is to establish a look-back period for the 
assessment of covariates such as a previous history of infection. Patients were 
followed starting from the cohort entry date until 12-months or until the outcome of 
interest occurred, whichever event came first.  
Lastly, both cases and controls were required to have ≥1 medical or prescription 
claim for an anti-TNF agent (adalimumab, etanercept, or infliximab) occurring after 
the RA cohort entry date and before the outcome of interest. This inclusion criteria 
was applied in order to increase our specificity of RA case ascertainment and to 
establish temporality that both cases and controls were exposed to an anti-TNF agent 
prior to the outcome of interest (hospitalized infection). As controls do not experience 
the outcome of interest, each matched control was assigned the same index date 
(defined as the date of the first hospitalized infection in cases) as its matched case. 
Further details on identification of cases and controls are presented in the next section. 
Patients were excluded for loss of coverage or inpatient death occurring ≤12 
months after the cohort entry date. Patients were also excluded if they had a diagnosis 
±12-months of the cohort entry date for another condition for which adalimumab, 
etanercept, and infliximab are approved, including Crohn’s disease, ulcerative colitis, 
psoriatic arthritis, plaque psoriasis, or ankylosing spondylitis.25 Patients were also 
excluded if they had a diagnosis ± 12-months of the cohort entry date for malignant 
neoplasm26 (for ICD-9-CM codes of exclusion criteria, see Appendix 2). The 
previously mentioned exclusion criteria for comorbidities was introduced to increase 
the homogeneity of the sample because RA patients with other autoimmune and 
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inflammatory conditions may have different infection risk profiles and infection-
related risk factors. 
Identification of Cases and Controls 
Cases and controls were derived from the aforementioned RA cohort (for a 
timeline of the nested case-control design, please see Figure 2). Cases were defined as 
patients who had an inpatient hospital admission code in any position for infection in 
the 12-months following the cohort entry date. The outcome of interest for cases was 
restricted to only the earliest hospitalized infection. Outcome events were identified 
using a comprehensive set of ICD-9 codes developed as part of a systematic literature 
review and two validation studies to identify serious infections in RA patients (for 
ICD-9-CM codes, see Appendix 3). This particular infection algorithm has 
demonstrated positive predictive values of ≥80%.27 For each case, an index date was 
assigned corresponding to the date of the inpatient hospital admission.  
Controls included those not experiencing a hospitalized infection in the 12-
months following the cohort entry date. Controls were randomly matched (without 
replacement) to cases on a 1:1 ratio based on gender, geographic region, and cohort 
entry date (quarter, year). Since the controls do not experience the outcome of interest, 
hospitalized infection, each matched control was assigned the same index date as its 
matched case. 
Drug Exposure Determination and Potential Predictors 
Cases and controls were considered exposed to an anti-TNF agent if they had ≥1 
pharmacy or medical claim for adalimumab, etanercept, or infliximab in the 90-days 
prior to the index date. Patients could be exposed to ≥1 anti-TNF agent during this 90-
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day exposure risk window. The self-injectable drugs adalimumab and etanercept were 
identified based on pharmacy claims for prescription fills (see Appendix 4). 
Adalimumab and etanercept were also identified based on medical claims considering 
the fact that when adalimumab and etanercept are first prescribed to a patient, the first 
injection is administered as part of a training session for the patient in an office setting 
under the supervision of a health care professional.17,18 The exposure risk window for 
adalimumab and etanercept will need to capture the possibility of the first dose being 
administered in the office in addition to prescription fills. The infused drug infliximab 
was identified based on medical claims, specifically the common procedure codes 
(CPT) 96413 and 96415 for the 1st and 2nd hour of infusion, respectively.28 
Potential predictors were selected based on general risk factors associated with 
the etiology of RA and the relevant published literature12,21-24. Although previous 
studies have shown an increased risk of infection correlated with disease severity 
measures such as disease activity score 28 (DAS28), health assessment questionnaire 
(HAQ), and visual analogue scale (VAS), these measures of disease activity were not 
available from the ClinformaticsTM DataMart (OptumInsight, Eden Prairie, MN). 
Gender and geographic region (Northeast, Midwest, South, and West) were selected as 
matching variables, therefore they were not assessed as risk factors. To ascertain 
potential predictors of hospitalized infection in RA patients using anti-TNF drugs, the 
following covariates were collected for each case and control: 
 Age 
 Number of rheumatologist visits from RA cohort entry date to index date   
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 Previous infection: hospitalized infection occurring ≤12-months prior to the RA 
cohort entry date 
 Joint replacement ≤360 days prior to index date 
 Exposure to specific anti-TNF medications: adalimumab, etanercept, and/or 
infliximab, ≤90 days prior to index date 
 Exposure to disease modifying anti-rheumatic drugs (DMARDs), or 
corticosteroids: methotrexate, azathioprine, leflunomide, hydroxychloroquine, 
sulfasalazine, prednisone, ≤90 days prior to index date 
 Comorbidities: diabetes, chronic kidney disease (CKD), obstructive pulmonary 
disorder (COPD), ≤90 days prior to index date 
 Prevalent or incident user of anti-TNF drug:  
o Prevalent (new) user: ≥1 claim for exposed anti-TNF drug(s) occurring 
between cohort entry date and 90-day exposure period 
o Incident (continuing) user: 0 claims for exposed anti-TNF drug(s) occurring 
between cohort entry date and 90-day exposure period 
Statistical Analysis 
Differences in the distribution of covariates among cases and controls was 
assessed using Chi-squared tests for categorical variables and two-sample t-tests for 
continuous variables. Conditional logistic regression was performed to assess the 
relationship between the dependent variable, the first hospitalized infection, with the 
independent risk factors described above. Multivariable conditional logistic regression 
was performed with inclusion of variables with a p-value ≤0.20 in the univariable 
models. A manual, backward, step-wise elimination was carried out to remove 
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variables with a Wald p-value >0.05 to produce a final multivariable model of 
variables significantly associated with the dependent variable. To determine goodness 
of fit, Akaike information criteria (AIC) values were compared between competing 
models and a Hosmer-Lemeshow test was used to assess the final model fit. 
Collinearity was assessed in the final model to determine if any of the independent 
variables were highly correlated with one another. A variance inflation factor (VIF) 
≥10 and/or a tolerance (TOL) value ≤0.10 would indicate variables with possible 
collinearity.29 The odds ratios (OR) for hospitalized infection risk for each risk factor 
was calculated with 95% confidence intervals and a p-value <0.05 was considered 
statistically significant. Statistical analyses were performed using SAS® Version 9.4. 
(Cary, NC). 
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CHAPTER 4 
 
FINDINGS 
 
Study Population Characteristics 
There were 176,745 patients initially identified as having ≥1 RA diagnosis during 
the study time frame of January 1, 2010 to December 31, 2013 (for study population 
flow chart, see Figure 3). All RA patients initially identified were age 18-63 years old. 
All RA patients initially identified also had ≥2 RA diagnoses separated by >7 days and 
occurring within 1 year of each other. Therefore, no patients were excluded based on 
inclusion criteria involving age or RA diagnoses. We then excluded patients who did 
not have continuous enrollment in the 12-months before their first RA diagnosis and 
the 12-months after their first RA diagnosis (N=97,752). Next, patients with a 
diagnosis ± 12-months of the RA cohort entry date for Crohn’s disease, ulcerative 
colitis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, or malignant 
neoplasm were excluded (N=336). We then excluded patients without ≥1 prescription 
or medical claim for an anti-TNF agent occurring in the 12-months after the RA 
cohort entry date (n=63,476) resulting in a final eligible RA cohort of 15,181 patients.  
Next, we identified cases as the patients who experienced a hospitalized infection 
occurring between the patient’s RA cohort entry date and the end of the 1-year follow 
up period. A total of 255 eligible cases was identified. Next, we excluded eligible 
cases and controls who did not have ≥1 prescription or medical claim for an anti-TNF 
agent occurring between the RA cohort entry date and the index date (n=965). After 
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all inclusion and exclusion criteria were applied, one control was matched to each case 
according to the matching variables gender, region, and cohort entry date (quarter, 
year). We were able to identify 155 cases matched on a 1:1 ratio to 155 controls. 
The demographic and clinical characteristics of cases and control are presented in 
Table 1. Cases and controls did not differ significantly in regards to age (p=0.6877) 
with both cases and controls having a mean age of approximately 45 years old. The 
majority of cases (56.13%) and controls (62.58%) had ≥2 rheumatologist visits 
between their RA cohort entry date and their index date, and this difference was not 
statistically significant (p=0.5048). Both cases and controls were mostly female 
(75.48%) and from the South (50.32%). Adalimumab use (p=0.6556) and infliximab 
use (p=0.4030) did not differ significantly between cases and controls. However, 
etanercept use differed significantly between cases and controls (15.48% cases, 
25.81% controls; p=0.0248). Prednisone use was significantly higher in cases 
compared with controls (31.61% cases, 21.29% controls; p=0.0394). Cases had a 
significantly higher frequency of comorbid conditions including diabetes (30.32% 
cases, 10.97% controls; p=<0.0001) and COPD (25.16% cases, 3.23% controls; 
p=<0.0001). Cases also experienced a significantly higher frequency of previous 
infection compared with controls (10.97% cases, 1.29% controls; p=0.0004).  
Univariable Analysis 
In univariable logistic regression, we identified covariates having a statistically 
significant association with the occurrence of hospitalized infection. Results of the 
univariable analysis of potential risk factors are presented in Table 2. Covariates with 
a p-value ≤0.20 were considered for building multivariable models. Based on 
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univariable comparison of cases and controls; age, etanercept use, methotrexate use, 
prednisone use, comorbid diabetes, comorbid chronic kidney disease, comorbid 
COPD, joint replacement, and previous history of infection were considered for the 
multivariable model.  
Univariable analysis of incident user and prevalent user of anti-TNF agents was 
not statistically significant (p=0.3551). However, the covariate, incident user, was 
forced into the initial multivariate model to assess whether incident user could be used 
to create an interaction term with etanercept use in the event that both main effects 
were statistically significant in multivariable analysis. A significant interaction 
between incident user and etanercept use would indicate that there is evidence that 
hospitalized infection in patients using etanercept is related to whether the patient is an 
incident user of etanercept.   
Multivariable Analysis 
Multivariable conditional logistic regression models were built to examine the 
association between anti-TNF drug use and the occurrence of serious infection 
requiring hospitalization. Results of the final model are presented in Table 3.  
RA patients with recent prednisone use were 1.873 times more likely to have a 
hospitalized infection (95% CI 1.015-3.458). Patients with comorbid diabetes were 
2.963 times more likely to experience a hospitalized infection (95% CI 1.445-6.078) 
and patients with comorbid COPD were 9.233 times more likely to experience a 
hospitalized infection (95% CI 2.755-30.947). Lastly, patients with a previous history 
of infection were 8.984 times more likely to have a hospitalized infection (95% CI 
1.895-42.595). 
 18 
 
Collinearity was assessed in the final model to determine if any of the 
independent variables were highly correlated with one another. The variance inflation 
factors (VIF) were all well under 10 and the tolerance (TOL) values were all greater 
than 0.10. Therefore, there was no evidence of collinearity based on VIF and TOL. 
Lastly, a Hosmer-Lemeshow test was performed on the final model to determine if the 
model was an adequate fit for the data. The Hosmer-Lemeshow test produced a p-
value of 0.6925, which is greater than 0.05. Therefore, there was no evidence that our 
model fits inadequately based on this test.  
Discussion 
Anti-TNF agents are effective for the treatment of RA, but may increase the risk 
for serious infections. The FDA requires manufacturers of anti-TNF agents to include 
black box warnings alerting health care professionals and patients of the risk of serious 
infections leading to hospitalization or death when using anti-TNF agents.17-19 A 
number of randomized clinical trials have demonstrated this increased risk. In a meta-
analysis of 44 randomized, double-blind, controlled trials of patients with RA that 
evaluated anti-TNF use, anti-TNF agents as a group was associated with a higher risk 
of serious infection (Odds ratio [OR] 1.42, 95% confidence interval [CI] 1.13-1.78) 
compared with placebo and traditional disease-modifying anti-rheumatic drug 
treatments (DMARDs).30  
Based on previous studies in other patient populations, we hypothesized that in 
RA patients using anti-TNF agents, the odds of hospitalized infection would be greater 
in patients with older ages, corticosteroid use, disease modifying anti-rheumatic drug 
 19 
 
(DMARD) use, and comorbidities such as diabetes mellitus, chronic kidney disease, 
and chronic obstructive pulmonary disorder (COPD). 
We assessed the association between anti-TNF use in RA patients and the 
increased risk of hospitalized infections in a large national privately insured 
population. Significant predictors of hospitalized infection in RA patients using anti-
TNF agents were prednisone use, comorbid diabetes, comorbid COPD, and previous 
history of infection.  
In relation to existing research, our findings are in agreement with studies that 
report an increased risk of serious infections in RA patients with prednisone use, 
diabetes, COPD, and previous history of infection.  
In a retrospective cohort study by Favalli et al21 to assess the incidence of serious 
infection in patients treated with anti-TNF agents, significant predictors of an 
increased risk of infection included prednisone use (Hazard ratio [HR] 2.89, 95% CI 
1.12–7.48). Similarly, Atzeni et al22 conducted a retrospective cohort study to evaluate 
the risk of serious infection in RA patients using anti-TNF agents and also found that 
the use of corticosteroids (HR 1.63, 95% CI 1.01-2.64) was a significant predictor of 
an increased risk of infection. In a nested case-control conducted by Widdifield et al23 
comparing senior RA patients with incident serious infection to matched controls, 
significant predictors of an increased risk of infection were chronic lung disease (OR 
1.31, 95% CI 1.25-1.36), previous history of infection (OR 1.51, 95% CI 1.45-1.57), 
and prednisone use (OR 3.96 at low doses, 95% CI 3.67-4.27; OR 7.57 at high doses, 
95% CI 6.87-8.34). In a retrospective cohort study by van Dartel et al24 to identify 
potential predictors of an increased risk of infection in RA patients using anti-TNF 
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agents, significant predictors of an increased risk of infection were corticosteroid use 
(HR 1.54, 95% CI 1.08-2.20) and the presence of comorbidities (diabetes, COPD, and 
cardiovascular disease were assessed as a single variable) (HR 1.31, 95% CI 0.98-
1.175).  
We did not identify an independent association between the increased risk of 
hospitalized infection and the use of specific anti-TNF agents. There is not a 
consistent consensus as to whether the risk of serious infections differs between 
adalimumab, etanercept, and infliximab with earlier studies reporting conflicting 
results. In studies that have assessed potential differences in risk between anti-TNF 
agents, Favalli et al21 reported no statistically significant difference in risk between 
adalimumab, etanercept, or infliximab. On the contrary, Atzeni et al22 demonstrated 
that the use of infliximab (HR 4.20, 95% CI 2.71-8.91) or adalimumab (HR 2.22, 95% 
CI 1.12-4.42) when compared to the use of etanercept were strong and significant 
predictors of infection.  
Demographic and patient characteristics unique to our RA cohort, as well as other 
limitations of the study design may be contributing factors as to why our results 
differed from previous studies. In regards to increased age as a potential predictor, we 
were unable to find an association between an increased risk of serious infection and 
older age. Previous studies that evaluated age as a continuous variable like our study 
have shown patients with increased age are at a higher risk of serious infection with an 
adjusted hazard ratio of approximately 1.03.21,22  Another study that evaluated age as a 
categorical variable showed patients >65 years old were at an approximately two-fold 
higher risk of experiencing a serious infection compared to patients <55 years old.24 A 
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potential reason as to why we were unable to find an association between the 
occurrence of serious infection and increased age may be attributed to the younger and 
narrower age range of our study sample, which only included patients aged 44-48 with 
an average age of approximately 45 years old in both our case and control groups.  
Although our final eligible RA cohort was relatively large, a fairly small number 
of hospitalized infection events (1.7%) were identified resulting in a smaller sample 
size for our nested case-control design. Our smaller sample size contributed to wide 
confidence intervals of the effect estimates from our final multivariable model and 
may have limited our power to detect an association between anti-TNF use and 
additional potential predictors. If we were able to identify a substantially larger sample 
size, we could have potentially identified more predictors, but the strength of the 
association related to many additional predictors may be weaker. Our study was able 
to identify strong and significant predictors of infection, particularly in patients with 
comorbid COPD and previous history of infection despite our small sample size and 
resultant wide confidence intervals.  
In addition, the nested case-control design means that causality cannot be 
explicitly inferred between anti-TNF use and hospitalized infection as not all relevant 
risk factors are captured and recorded within the dataset. Therefore, it is not possible 
to measure and control for all factors that may have influenced the occurrence of 
hospitalized infection. 
Furthermore, previous studies have found measures of RA disease severity to be 
significant predictors of hospitalized infection in patients using anti-TNF drugs. 
However, the ClinformaticsTM DataMart does not directly capture indicators of disease 
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severity. We included proxies of disease severity as potential predictors in our 
analyses, such as the number of rheumatologist clinic visits from RA cohort entry date 
to index date, prednisone use, and presence of comorbidities. In addition, there is no 
evidence that confounding by indication is a concern according to the type of anti-
TNF agent. The 2015 American College of Rheumatology (ACR) recommendations 
do not indicate a particular order of preference when prescribing an anti-TNF agent to 
a patient based on disease severity.31 Future research may be directed towards further 
analyses using disease risk scores as a stronger proxy for disease severity.  
Strengths of our study include the use of validated ICD-9 codes with proven high 
positive predictive values for disease to identify cases of hospitalized infection in 
administrative data, which may reduce potential misclassification bias. In addition, the 
use of a large privately insured population allows for more generalizable results for 
RA patients using anti-TNF agents in the US as opposed to studies that use data 
sources outside of the US. However, this also means that the results cannot be 
extrapolated towards patient populations beyond the privately insured. Furthermore, 
our results are not representative of older patient populations like those represented in 
Medicare. Our results are only generalizable to a population representative of our final 
patient sample such as being predominantly female, younger, from the South, and 
privately insured RA patients in the United States when most previous studies have 
analyzed populations outside of the US. 
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CHAPTER 5 
 
CONCLUSION 
 
Anti-TNF agents are known to inhibit the function of tumor necrosis factor, 
which can lead to a reduction of joint damage and inflammation in RA patients using 
these agents. However, serious infections have been reported in patients using anti-
TNF drugs.  
In our patient cohort, we were unable to identify a significant association between 
the increased risk of hospitalized infection and specific anti-TNF use in RA patients. 
Significant predictors of hospitalized infection in RA patients using anti-TNF agents 
included recent prednisone use, diabetes, COPD, and previous history of infection. 
The impact of these findings suggest that careful monitoring of these specific patient 
populations may be important in reducing the occurrence of hospitalized infection 
among patients using anti-TNF agents. 
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TABLES 
TABLE 1: Demographic and clinical characteristics of RA patients – cases and 
controls (N=310) 
Variable Cases  
n=155 
Frequency (%) 
Controls  
n=155 
Frequency (%) 
p-value 
Age, mean ± SD 45.51 ± 1.13 45.56 ± 1.13 0.6877 
Male gender 38 (24.52) 38 (24.52) 1.0000 
Number of rheumatologist visits from RA 
cohort entry date to index date: 
 
     0 visit 28 (18.06) 23 (14.84) 0.5048 
     1 visit 40 (25.81) 35 (22.58) 
     ≥ 2 visits 87 (56.13) 97 (62.58) 
Region:  
     Northeast 9 (5.81) 9 (5.81) 1.0000 
     Midwest  39 (25.16) 39 (25.16) 
     South 78 (50.32) 78 (50.32) 
     West  29 (18.71) 29 (18.71) 
Anti-TNF drug exposure 90 days prior to 
index date 
 
     Adalimumab 26 (16.77) 29 (18.71) 0.6556 
     Etanercept 24 (15.48) 40 (25.81) 0.0248 
     Infliximab 57 (36.77) 50 (32.26) 0.4030 
Other drug exposure 90 days prior to 
index date 
 
     Methotrexate  38 (24.52) 51 (32.90) 0.1027 
     Prednisone 49 (31.61) 33 (21.29) 0.0394 
     Azathioprine 1 (0.65) 2 (1.29) 0.5618 
     Leflunomide 5 (3.23) 5 (3.23) 1.0000 
     Hydroxychloroquine 17 (10.97) 15 (9.68) 0.7089 
     Sulfasalazine 5 (3.23) 8 (2.58) 0.3953 
Comorbidities  
     Diabetes mellitus  
     (90 days prior to index date) 
47 (30.32) 17 (10.97) <.0001 
     Chronic kidney disease  
     (90 days prior to index date) 
10 (6.45) 5 (3.23) 0.1857 
     Chronic obstructive pulmonary       
     disorder   
     (90 days prior to index date) 
39 (25.16) 5 (3.23) <.0001 
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TABLE 1 (continued): Demographic and clinical characteristics of RA patients – 
cases and controls (N=310) 
Variable Cases  
n=155 
Frequency (%) 
Controls  
n=155 
Frequency (%) 
p-value 
     Joint replacement  
     (360 days prior to index date) 
7 (4.52) 2 (1.29) 0.0908 
     Previous history of infection 
     (hospitalized infection 12 months prior to  
      cohort entry date) 
17 (10.97) 2 (1.29) 0.0004 
Prevalent or incident user of anti-TNF drug  
      Incident  
      (0 claims for exposed anti-TNF drug(s)  
       between cohort entry date and 90-day  
       exposure period) 
82 (52.90) 75 (48.39) 0.4265 
      Prevalent 
      (≥1 claim for exposed anti-TNF drug(s)  
       between cohort entry date and 90-day  
       exposure period) 
73 (47.10) 80 (51.61) 0.4265 
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TABLE 2: Univariable logistic regression analysis of covariates 
Variable Univariable Model  
Odds Ratio 
95% Confidence 
Interval (CI) 
Unadjusted 
p-value 
Age 0.111 0.014-0.877 0.0371 
Number of rheumatologist visits from RA 
cohort entry date to index date (ref=0) 
 
     1 visit 1.063 0.487-2.321 0.8783 
     ≥ 2 visits 0.695 0.365-1.323 0.2682 
Anti-TNF drug exposure 90 days prior to 
index date 
 
     Adalimumab 0.870 0.478-1.583 0.6476 
     Etanercept 0.500 0.274-0.911 0.0236 
     Infliximab 1.269 0.759-2.122 0.3633 
Other drug exposure 90 days prior to 
index date 
 
     Methotrexate  0.658 0.397-1.090 0.1040 
     Prednisone 1.640 0.997-2.697 0.0512 
     Azathioprine 0.500 0.045-5.514 0.5714 
     Leflunomide 1.000 0.290-3.454 1.0000 
     Hydroxychloroquine 1.167 0.540-2.522 0.6952 
     Sulfasalazine 0.625 0.204-1.910 0.4097 
Comorbidities  
     Diabetes mellitus  
     (90 days prior to index date) 
3.308 1.779-6.151 0.0002 
     Chronic kidney disease  
     (90 days prior to index date) 
2.250 0.693-7.306 0.1772 
     Chronic obstructive pulmonary       
     disorder  
     (90 days prior to index date) 
12.333 3.803-40.000 <.0001 
     Joint replacement  
     (360 days prior to index date) 
3.500 0.727-16.848 0.1182 
     Previous history of infection 
     (hospitalized infection 12-months prior  
      to cohort entry date) 
8.500 1.964-36.790 0.0042 
Prevalent or incident user of anti-TNF 
drug 
 
      Prevalent 
      (≥1 claim for exposed anti-TNF  
      drug(s) between cohort entry date 
      and 90-day exposure period) 
0.781 0.463-1.318 0.3551 
      Incident  
      (0 claims for exposed anti-TNF 
      drug(s) between cohort entry date  
      and 90-day exposure period) 
1.280 0.759-2.160 0.3551 
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TABLE 3: Final multivariable logistic regression analysis of covariates with manual, 
backward, step-wise elimination to remove variables with a P-value >0.05 
Variable Multivariate Model  
Odds Ratio 
95% Confidence 
Interval (CI) 
Adjusted 
p-value 
Other drug exposure 90 days prior to 
index date 
 
     Prednisone 1.873 1.015-3.458 0.0447 
Comorbidities  
     Diabetes mellitus  
     (90 days prior to index date) 
2.963 1.445-6.078 0.0030 
     Chronic obstructive pulmonary       
     disorder  
     (90 days prior to index date) 
9.233 2.755-30.947 0.0003 
     Previous history of infection 
     (hospitalized infection 12   
      months prior to cohort entry  
      date) 
8.984 1.895-42.595 0.0057 
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FIGURES 
FIGURE 1: Timeline of RA cohort 
 
RA= rheumatoid arthritis  
Anti-TNF = anti-tumor necrosis factor 
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FIGURE 2: Timeline of nested case-control study 
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FIGURE 3: Study sample selection flowchart 
 
RA = rheumatoid arthritis 
Anti-TNF = anti-tumor necrosis factor 
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APPENDICES 
APPENDIX 1: Literature review table 
Author, 
Year 
Design Population Inclusion/Exclusion 
Criteria 
Exposure/Outcome Definition Significant Predictors 
Curtis et 
al12, 
2007 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Retrospective 
cohort 
 
 Medical and 
pharmacy 
administrative 
claims of 
large US 
health 
organization  
between 
May 1998 and 
December 
2003 
Inclusion: 
 ≥18 years old 
 ≥2 RA diagnoses 
 Each individual had to 
have received an 
infusion or filled 
a prescription for an 
anti-TNF drug or 
filled at least 3 
prescriptions for 
methotrexate 
Follow up: 
 Infections identified within 6 
months of the most recent 
exposure to the anti-TNF or 
methotrexate 
Exposure: 
 Patients who received an anti- 
TNF drug were the exposed 
cohort and those who received 
methotrexate only were the 
unexposed/comparator cohort 
 Date of 1st exposure to the anti-
TNF  
Outcome: 
 Identified hospitalizations that 
occurred after index date with 
≥2 ICD-9-CM codes for 
bacterial infections (at least 1 of 
these codes had to be based on a 
face-to-face encounter with a 
physician, additional ICD-9-CM 
codes could originate from a 
claim for a diagnostic test or 
procedure) 
 
Multivariate analysis: 
 Anti-TNF treatment (HR 1.94, 95% CI 
1.32–2.83) 
 Age (5-year increments) (HR 1.14, 95% 
CI 1.03–1.27) 
 No. of face-to-face physician visits (HR 
1.04, 95% CI 1.01–1.07) 
 Prior infection (HR 1.46, 95% CI 0.85 
2.51) 
 Chronic obstructive pulmonary disease 
or asthma (HR 1.90, 95% CI 1.19–3.04) 
 Diabetes mellitus (HR 1.75, 95% CI 
1.10–2.78) 
 Kidney disease (HR 3.23, 95% CI 1.35–
7.73) 
 Decubitus ulcer (HR 3.05, 95% CI 
1.50–6.19) 
 Mean prednisone dosage 
- ≤5 mg/day (HR 1.49, 95% CI 0.82–  
      2.72 
- 5–10 mg/day (HR 1.46, 95% CI 0.84– 
      2.54) 
- ≥10 mg/day (HR 1.85, 95% CI 1.2– 
      2.85) 
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Author, 
Year 
Design Population Inclusion/Exclusion 
Criteria 
Exposure/Outcome Definition Significant Predictors 
Favalli et 
al21, 
2009 
Retrospective 
cohort   
 Lombardy 
(Italy) 
Rheumatology 
Network 
(LORHEN) 
registry (since 
1999) 
 
Inclusion: 
 ≥1 diagnosis of RA 
and ≥ 18 years old 
 ≥1 infusion or filled a 
prescription for 
etanercept, infliximab, 
or adalimumab 
 All patients treated in 
accordance with the 
Italian Society of 
Rheumatology 
guidelines for the use 
of anti-TNFα agents: 
Failure to respond to 
≥1 course of 
combination therapy 
with full-dose 
traditional DMARDs, 
one of which is 
methotrexate unless 
contraindicated and 
disease Activity Score 
on 28 joints (DAS28) 
of >3.5  
Exclusion:  
 Active infection 
and/or history of 
malignancy or a pre-
malignant condition, 
class III/IV congestive 
heart failure, or 
demyelinating 
disorders 
 
Follow up: 
 Followed for 1st administered 
anti-TNF agent until 36 months 
or first infection outcome 
Exposure: 
 1st administered dose of 
adalimumab, etanercept, or 
infliximab 
Outcome: 
 Physician documented infection 
episodes recorded in medical 
charts or outpatient visits 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Multivariate analysis: 
 Age (per 1 year) (HR 1.03/year, CI 
1.01–1.06) 
 Prednisone daily dose > 5 mg (HR 2.89, 
95% CI 1.12–7.48) 
 Erythrocyte sedimentation rate (ESR) 
(HR 1.02 per every mm/h increase, 95% 
CI 1.00–1.03) 
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Author, 
Year 
Design Population Inclusion/Exclusion 
Criteria 
Exposure/Outcome Definition Significant Predictors 
Atzeni et 
al22, 
2012 
Retrospective 
cohort 
 GISEA (Italy) 
registry (since 
2008) 
Inclusion:  
 ≥18 years 
 RA diagnosis by 
rheumatologist 
 ≥1 infusion or filled a 
prescription for 
etanercept, infliximab, 
or adalimumab 
 All patients treated ≥6 
months with anti-TNF 
agent or had 
discontinued anti-TNF 
earlier due to infection  
 All patients treated in 
accordance with the 
Italian Society of 
Rheumatology 
guidelines for the use 
of anti-TNF agents:  
- Failure to respond to 
at least one course of 
combination therapy 
with full-dose 
traditional DMARDs, 
one of which is 
methotrexate unless 
contraindicated 
- Disease Activity 
Score on 28 joints 
(DAS28) of >3.5  
 
 
 
 
Follow up: 
 Followed for 1st administered 
anti-TNF agent until first 
infection outcome 
Exposure: 
 1st infusion of infliximab or 
filled prescription for 
adalimumab or etanercept 
 If patients switched to 2nd anti-
TNF agent, only time and 
adverse events of 1st agent used 
in analysis 
Outcome: 
 Physician documented infection 
episodes, occurrence of adverse 
events captured every 6 months 
 
Multivariate analysis: 
 Corticosteroid therapy (OR 1.633, 95% 
CI 1.01-2.644) 
 Concomitant DMARD during anti-TNF 
treatment (OR 2.14, 95% CI 1.28-
3.595) 
 Age at start of anti-TNF treatment (OR 
1.036, 95% CI 1.02-1.053) 
 Use of infliximab (OR 4.916, 95% CI 
2.71-8.906) or adalimumab (OR 2.22, 
95% CI 1.12-4.42) rather than 
etanercept 
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Author, 
Year 
Design Population Inclusion/Exclusion 
Criteria 
Exposure/Outcome Definition Significant Predictors 
Widdifiel
d et al23, 
2013 
Nested case-
control 
 Ontario health 
administrative 
data 
 April 1, 1992 
to March 31, 
2010 data 
analysis 
Inclusion:  
 ≥66 years   
 ≥2 billing code 
diagnoses of RA >60 
days apart, but within 
5 years 
 ≥1 prescription for an 
oral glucocorticoid, a 
DMARD, or a 
biologic agent 
 
Follow up: 
 Followed on date when all 
inclusion/exclusion criteria were 
met until outmigration, death, or 
the end of the study (March 31, 
2010) 
Exposure: 
  Oral glucocorticoid, DMARD, 
or biologic ≤365 days before 
index date 
Outcome: 
 Cases: Emergency department 
visit or hospital admission with 
primary diagnosis of infection 
between the later of April 1, 
1998, or cohort entry, and 
March 1, 2010 
 Controls: Cases matched on age 
(±5 years), sex, and date of 
cohort entry (±1 year) to 5 
controls from the same RA 
cohort 
 
 
 
 
 
 
 
 
 
 
 
 
Multivariate analysis: 
 Rural (ref. urban) (OR 1.51, 95% CI 
1.44–1.58) 
 Comorbidities 
- Diabetes Mellitus (OR 0.97, 95% CI 
0.93–1.01) 
- Chronic lung disease (OR 1.31, 95% 
CI 1.25–1.36) 
- Renal disease (OR 1.26, 95% CI 1.18-
1.36) 
 Current glucocorticoid use (mg/day)  
- ≤5 (OR 3.96, 95% CI 3.67–4.27) 
- ≥20 (OR 7.57, 95% CI 6.87–8.34) 
 Current methotrexate use (mg/day)  
- ≤10 (OR 2.38, 95% CI 2.22–2.56) 
- >10 (OR 2.97, 95% CI 1.90–4.64) 
 Current anti-TNF use (OR 1.60, 95% 
CI 1.19-2.15) 
 Extra articular features of RA (OR 1.11, 
95% CI 1.07–1.16) 
 Joint replacements (OR 1.01, 95% CI 
0.97–1.06) 
 Previous infections (OR 1.51, 95% CI 
1.45–1.57) 
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Author, 
Year 
Design Population Inclusion/Exclusion 
Criteria 
Exposure/Outcome Definition Significant Predictors 
van 
Dartel et 
al24, 
2013  
Retrospective 
cohort 
 Dutch 
Rheumatoid 
Arthritis 
Monitoring 
(DREAM) 
biologic 
registry (since 
2003)  
 Radboud 
University 
Nijmegen 
Medical 
Centre 
(RUNMC) 
(before 2003) 
 5-year data 
analysis 
 
Inclusion:  
  Using adalimumab, 
infliximab or 
etanercept as 1st anti-
TNF agent  
Exclusion:  
 Received anti-TNF 
agent as part of a 
clinical trial. 
 
 
Follow up: 
 Followed for 1st administered 
anti-TNF agent until 5 years of 
observation time or at the end of 
follow-up, or after stop of an 
anti-TNF agent plus five times 
the half-life, or after the 
occurrence of the 1st serious 
infection 
 Patients who switched between 
anti-TNF agents, the treatment 
with the next anti-TNF 
contributed to the observation 
time if it started within five 
times the half-life of the former 
anti-TNF agent 
Exposure: 
 1st administered dose of 
adalimumab, etanercept, or 
infliximab 
Outcome: 
 FDA definition for serious 
adverse event: hospitalization 
and/or intravenous antibiotic 
treatment, life threatening, 
disabling daily activities 
 
Multivariate analysis: 
 Age (ref. <55) 
- 55-65 (HR 1.07, 95% CI 0.66-1.74) 
- >65 (HR 2.11, 95% CI 1.39-3.22) 
 Corticosteroid use baseline (HR 1.54, 
CI 1.08-2.20) 
 Visual analogue scale (VAS) pain 
baseline (HR 0.98, CI 0.98-1.00) 
 Health Assessment Questionnaire 
(HAQ) baseline (HR 1.57, CI 1.12-
2.22) 
 Tender joint count 28 joints (TJC28) 
(HR 1.04, CI 1.01-1.06) 
 Presence of comorbidities (HR 1.31, CI 
0.98-1.75) 
Anti-TNF = anti-tumor necrosis factor 
CI = confidence interval 
DMARD = disease modifying anti-rheumatic drug 
HR = hazard ratio 
OR = odds ratio 
RA = rheumatoid arthritis 
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APPENDIX 2: ICD-9-CM codes to identify exclusion criteria diagnoses25,26 
Diagnosis ICD-9-CM Code 
Crohn’s disease 555.0 555.1 555.2 555.9 
Ulcerative colitis 556.0 556.1 556.2 556.3 556.4 556.5 556.6 556.8 
556.9 
Psoriatic arthritis  696.0 
Plaque psoriasis  696.1 
Ankylosing spondylitis 720.0 
Malignant neoplasm 140.x 172.x 173.00, 173.09 173.10, 173.19 173.20 
173.29 173.30 173.39 173.40 173.49 173.50 173.59 
173.60 173.69 173.70 173.79 173.80 173.89 173.90 
173.99 174.x 209.36 209.7x 
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APPENDIX 3: ICD-9-CM codes to identify hospitalized infection27 
Diagnosis ICD-9-CM Code 
Meningitis  003.21 036.0 049.0 091.81 094.2 098.82 320.xx 
Encephalitis  036.1 323.x 094.81 130 
Cellulitis 040.0 569.61 681.xx 682.x 785.4 035 608.4 681.xx 614.3 
528.3 566 597.0 
Endocarditis 036.42 093.2x 98.84 391.1 397.9 421.x 421.9 422.92  
Pneumonia 003.22 481.0 482.xx 483.x 485.x 486.x 513.0   
Pyelonephritis/urinary tract 
infection 
590.xx 599.0 
Septic arthritis  003.23 056.71 711.9x 711.0x 098.5x  
Osteomyelitis 003.24 730.2x 526.4 730.2x 526.4 730.0x 730.1x 376.03 
Bacteremia/septicemia 038.xx 041.xx 790.7 
Upper respiratory tract infection 34 381.5x 382.x 383.0x 383.1 383.9 461.x 462.x 463 
465.x 466 464.0x 472.x 473.x 475 510 510.9 
Abdominal abscess  95.2 540.1 569.5 567.x 572 590.2 601.2 614.4 998.59 
Brain abscess 324.x 
Cholecystitis 574.x 575 576.1 575.1x 575.1 575.12 575.11 
Prostate infections 98.32 98.12 131.03 601.x 
Gastroenteritis  001 002 003 003.0 004 005 008 008.1 008.2 008.4 008.5 
009.x 
Infectious conjunctivitis 372.0x 77.9 32.81  
Device-associated infections 996.6x 
Local infections of skin and 
subcutaneous tissue 
686.1 686.8 686.9 
Gangrene 785.4 
Retropharyngeal abscess 478.21 478.24 478.22 
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APPENDIX 3 (continued): ICD-9-CM codes to identify hospitalized infection27 
Diagnosis ICD-9-CM Code 
Breast abscess 611.0 
Splenic abscess 289.59 
Pyogenic granuloma 686.1 
Post-traumatic wound infection 958.3 
Postoperative wound infection 998.5 
Infective myositis 40.81 
Necrotizing fasciitis 728.86 
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APPENDIX 4: National drug codes (NDC) and Healthcare Common Procedure 
Coding System (HCPCS) codes to identify pharmacy or medical claims for the self-
injectable drugs adalimumab and etanercept 
Proprietary (Non-
Proprietary) Name 
11 Digit National Drug Code 
(NDC) 
Healthcare Common 
Procedure Coding 
System (HCPCS)  
Humira (adalimumab) 00074006702 
00074024302 
00074024371 
00074055401 
00074055402 
00074055404 
00074055406 
00074055471 
00074055473 
00074055474 
00074254001 
00074254003 
00074379701 
00074379902 
00074379903 
00074379906 
00074379971 
00074433901 
00074433902 
00074433906 
00074433907 
00074433971 
00074433973 
00074433974 
00074634702 
00074937402 
00074937471 
J0135  
Enbrel (etanercept) 58406042534 
58406043504 
58406044504 
58406045504 
J1438 
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